Kalpit Patel
Stock Analyst at B. Riley Securities
(1.87)
# 3,228
Out of 5,129 analysts
71
Total ratings
36.73%
Success rate
-7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $79.49 | +47.19% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.71 | +320.52% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $10.56 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $40.97 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $13.13 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $12.69 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $67.23 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $15.25 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $47.64 | -11.84% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $40.50 | +85.19% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $95.98 | -21.86% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $104.17 | +5.60% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $8.10 | +48.15% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $5.63 | +148.67% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $21.08 | +75.52% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $34.62 | -30.68% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.62 | +116.05% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $6.28 | +43.31% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.45 | +83.49% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $7.92 | +405.05% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.64 | +82.93% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $30.06 | -33.47% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.71 | +708.63% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $21.32 | +68.86% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.94 | +4,539.18% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.69 | +965.09% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.45 | +244.83% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $11.19 | +793.66% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $29.34 | +155.62% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $79.49
Upside: +47.19%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.71
Upside: +320.52%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $10.56
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $40.97
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $13.13
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $12.69
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $67.23
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $15.25
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $47.64
Upside: -11.84%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $40.50
Upside: +85.19%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $95.98
Upside: -21.86%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $104.17
Upside: +5.60%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $8.10
Upside: +48.15%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $5.63
Upside: +148.67%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $21.08
Upside: +75.52%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $34.62
Upside: -30.68%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.62
Upside: +116.05%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $6.28
Upside: +43.31%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.45
Upside: +83.49%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $7.92
Upside: +405.05%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.64
Upside: +82.93%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $30.06
Upside: -33.47%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.71
Upside: +708.63%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $21.32
Upside: +68.86%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.94
Upside: +4,539.18%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.69
Upside: +965.09%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.45
Upside: +244.83%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $11.19
Upside: +793.66%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $29.34
Upside: +155.62%